Status:
COMPLETED
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
Brief Summary
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
Eligibility Criteria
Inclusion
- Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar.
- Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment.
Exclusion
- Prior targeted therapy for RCC
- Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).
Key Trial Info
Start Date :
July 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01508364
Start Date
July 1 2012
End Date
December 1 2013
Last Update
January 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Germany